Article Text

Download PDFPDF

Biologic therapies for juvenile arthritis
Free
  1. N Wilkinson1,
  2. G Jackson2,
  3. J Gardner-Medwin3
  1. 1Great Ormond Street Hospital, London, UK
  2. 2Leeds General Infirmary, UK
  3. 3Department of Child Health, Glasgow University, UK
  1. Correspondence to:
    Dr N Wilkinson, Department of Rheumatology, Great Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, UK;
    petherton{at}clara.co.uk

Abstract

A group of therapies with exciting potential has emerged for children and young people with severe juvenile idiopathic arthritis (JIA) uncontrolled by conventional disease modifying drugs. Theoretical understanding from molecular biologic research has identified specific targets within pathophysiological pathways that control rheumatoid arthritis (RA) and JIA. This review identifies the pathways of autoimmunity to begin to show how biologic agents have been produced to replicate, mimic, or block culpable molecules and so promote or inhibit cellular activity or proliferation. Of these agents, cytokine antagonists have shown greatest promise, and early clinical studies of tumour necrosis factor (TNF) blockade have identified dramatic clinical benefit in many children with JIA. However, as will also be discussed, overlap of pathways within a complex immune system makes clinical response unpredictable and raises additional ethical and administrative concerns.

  • IL, interleukin
  • JIA, juvenile idiopathic arthritis
  • RA, rheumatoid arthritis
  • TNF, tumour necrosis factor
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.